Tyropanoate Sodium
Tyropanoate sodium is an iodinated oral cholecystographic contrast agent that is taken up by the liver and concentrated in the bile and gallbladder, making these structures radiopaque for visualization on X-ray imaging. It was used for oral cholecystography to diagnose gallbladder disease and biliary tract disorders. Its iodine content also transiently inhibits thyroid hormone metabolism and was occasionally used to manage hyperthyroidism.
Peso molecular
663,0000 g/mol
TPSA
69,20 Ų
Mecanismo de acción
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CCCC(=O)Nc1c(I)cc(I)c(CC(CC)C(=O)[O-])c1I.[Na+]
InChI
InChI=1S/C15H18I3NO3.Na/c1-3-5-12(20)19-14-11(17)7-10(16)9(13(14)18)6-8(4-2)15(21)22;/h7-8H,3-6H2,1-2H3,(H,19,20)(H,21,22);/q;+1/p-1
Molecular Formula
C15H17I3NNaO3
HBD / HBA
1 / 3
Enlaces Rotables
7
Átomos Pesados
23
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Tyropanoate sodium is an iodinated oral cholecystographic contrast agent that is taken up by the liver and concentrated in the bile and gallbladder, making these structures radiopaque for visualization on X-ray imaging. It was used for oral cholecystography to diagnose gallbladder disease and biliary tract disorders. Its iodine content also transiently inhibits thyroid hormone metabolism and was occasionally used to manage hyperthyroidism.
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Yes, Tyropanoate Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200899. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 541384. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tyropanoate-sodium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tyropanoate-sodium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tyropanoate-sodium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tyropanoate-sodium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tyropanoate-sodium"></drugfyi-drug>